Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Expands Capacity, Adds Deal

by Ann M. Thayer
May 25, 2009 | A version of this story appeared in Volume 87, Issue 21

Lonza will spend about $27 million to build a new cell therapy facility at the Tuas Biomedical Park in Singapore. The plant will be Lonza's first for cellular therapeutics in Asia; the firm already has 12 current Good Manufacturing Practices-certified cell therapy manufacturing suites in the U.S. and Europe. Construction will begin in early 2010 with the initial start-up of two suites by mid-2011. Separately, Lonza has signed a deal with Morphotek, a subsidiary of Eisai, to develop and manufacture Morphotek's therapeutic antibodies. Morphotek's lead antibody, farletuzumab, recently entered Phase III clinical trials for ovarian cancer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.